NCT05395338

1-year Clinical Outcomes in Recombinant Tissue Plasminogen Activator (Rt-PA) Treated Chinese Acute Ischaemic Stroke (AIS) Patients

1-year Clinical Outcomes After Intravenous Rt-PA for Chinese AIS Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 12,551 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of the study is to find out the 1-year clinical outcomes among Acute Ischaemic Stroke (AIS) patients who were treated with intravenous (IV) Recombinant Tissue Plasminogen Activator (rt-PA) within 4.5 hours of symptom onset compared with those who arrived or were admitted to the hospital within 4.5 hours of symptom onset and did not receive any reperfusion treatment in a real-world clinical setting.

Conditions

• Stroke

Interventions

Type	Name	Description
DRUG	rt-PA	Recombinant Tissue Plasminogen Activator

Timeline

• Start date: 2022-04-12
• Primary completion: 2022-11-30
• Completion: 2022-11-30
• First posted: 2022-05-27
• Last updated: 2024-10-16
• Results posted: 2024-10-16

Locations

1 site across 1 country: China